Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS

Vasomune Therapeutics, a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, recently announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase 2a clinical study evaluating Pegevongitide (AV-001) in patients hospitalized with pneumonia requiring supplemental oxygen.

Vasomune Therapeutics is an alumnus of our BDSP™ and CAAP® programs, and presented at the OBIO® Investment Summit.

Previous
Previous

Hôpital Montfort establishes an innovative partnership to accelerate Emergency Department care

Next
Next

How AI Changes the Drug Discovery Equation